Siegfried Holding
| Siegfried Holding AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | CH0014284498 |
| founding | 1873 |
| Seat |
Zofingen , Switzerland
|
| management |
|
| Number of employees | 2,364 |
| sales | 794.3 million CHF (667 million euros ) |
| Branch | Pharmaceutical company |
| Website | www.siegfried.ch |
| As of December 31, 2018 | |
The Siegfried Holding AG is a world in the field of life science company with production sites in Switzerland , the United States , Malta , China , Germany and France . In the 2018 financial year, the company achieved sales of around CHF 800 million and employed around 2,300 people. Siegfried Holding AG is listed on the Swiss stock exchange.
Field of activity
Siegfried is active in both the primary and secondary production of pharmaceuticals . The company develops and produces active pharmaceutical ingredients for the research-based pharmaceutical industry , corresponding intermediate stages and controlled substances, and also offers development and manufacturing services for fully formulated drugs, including sterile filling.
history
In 1873 the pharmacist Samuel Benoni Siegfried founded a company with 12 employees to supply pharmacies . In 1904 the company was converted into a public limited company. In 1927 Ganes Chemical Works Inc. was founded in New Jersey . In 1973, Siegfried Holding was first traded on the SIX Swiss Exchange . In 2001 the holding was split up into the Siegfried and Sidroga divisions. A year later, the US company Ganes was included in the Siegfried Group and the name was changed to "Siegfried USA Inc". In 2004 Siegfried Holding set up a representative office in Shanghai , and in 2005 the Penick Corporation was bought. Siegfried has been working with Celgene since 2006 .
In 2007 Siegfried started up a pharmaceutical production facility in Malta. A laboratory unit for inhalation technology was also set up there. In the same year Siegfried sold the Sidroga division and the biotechnology division. A collaboration agreement has been signed with Arena Pharmaceuticals . Siegfried built a laboratory in Munich for the development of inhalation products. In 2008 the pharmaceutical production in Zofingen was sold .
With the definition of the new company strategy under the title " Transform" , Siegfried began restructuring in 2010. In addition to new investors and the associated capital increase, the Pulmojet project in Munich was sold to Sanofi-Aventis . Two years later, Alliance Medical Products (AMP) in Irvine , California was acquired .
A year later, Siegfried built a new production site in Nantong (China) and a new production facility at the headquarters in Zofingen.
In 2014, Siegfried acquired the German company Hameln Pharma , which is active in the development and manufacture of sterile liquid dosage forms for the pharmaceutical industry.
In May 2015, Siegfried bought the custom synthesis business and parts of the active ingredient production with the production sites in Minden (now Siegfried Pharma-Chemicals Minden ), Evionnaz and Saint-Vulbas from BASF . On October 1, 2015, BASF SE announced that the sale of custom synthesis and parts of its API business to Siegfried Holding AG had been completed.
With CHF 480.6 million, an increase of 52.4 percent, the Siegfried Group achieved the highest turnover in the company's history in 2015. At the AGM in April 2016, the Board of Directors through the election of Ulla Schmidt, member and Vice-President of the German Bundestag was, and Councilor Martin Schmid expanded to include two new members and now consists of seven people.
The production site in Nantong (China), which was built in 2013, received the final operating license for commercial production on a large scale from the Chinese authorities in May 2016. The turnover of Siegfried Holding AG in the first half of the year was CHF 353.6 million, which corresponds to an increase of 76.2 percent. The Minden (Germany), Evionnaz (Switzerland) and St. Vulbas (France) locations acquired in the previous year were integrated into the Siegfried IT infrastructure in the summer months.
In the third quarter of 2016, Siegfried Holding AG announced the placement of another subordinated public hybrid bond totaling 160 million francs. The net proceeds from the bond were used to repay existing bank loans and for capital structure management. The new production building in Zofingen was able to start production in October, which meant that older, inefficient systems could be moved. In October the Siegfried Group announced a change in the group management. Walter Kittl, who headed Global Technical Operations as a member of the Executive Committee, stepped down in October. René Imwinkelried, previously Head of Research & Development, has succeeded him. Siegfried Holding AG closed the 2016 financial year with a record turnover of 717.7 million francs and an increase of 49.3 percent.
In March 2017, the Siegfried Group announced two changes in its management. CFO Michael Hüsler left the company at the end of April 2017. The Board of Directors elected Reto Suter, who took over this role on May 1, 2017, as his successor. Also with effect from May 1, 2017, the Board of Directors has entrusted Wolfgang Wienand with the management of the Siegfried Group's global research and development activities. For the first half of 2017, the company reports higher operating profit (EBITDA) and a significantly higher margin with stable sales. Siegfried achieved net sales of 349.1 million francs, from 353.6 million francs in the same period of the previous year (minus 0.9 percent in local currencies and minus 1.3 percent in Swiss francs).
On October 27, 2017, Bernard A. Siegfried, long-time boss and honorary president of Siegfried Holding AG since 2003, passed away after a long and serious illness at the age of 83.
Siegfried closed the 2017 financial year with a very solid result. Sales amounted to CHF 750.5 million, an increase of 4.6 percent. After years of significant acquisitions, Siegfried has achieved robust organic growth. As of March 31, 2018, Siegfried took over the production facility for finished products (tablets and capsules) including all employees and business contracts from Arena Pharmaceuticals GmbH in Zofingen.
Individual evidence
- ↑ Management
- ↑ Board of Directors
- ↑ a b c Annual Report 2018 , accessed March 28, 2019
- ^ History of Pennsville . Siegfried Holding AG. Retrieved November 27, 2015.
- ^ Siegfried acquires Alliance Medical Products . AMP. Retrieved November 16, 2014.
- ↑ Siegfried buys Hameln Pharma . Siegfried Holding. Retrieved January 29, 2015.
- ↑ Press release BASF from May 7, 2015
- ↑ Press release BASF from October 1, 2015
- ^ Press release by Siegfried from March 22, 2016
- ^ Press release Siegfried from April 15, 2016
- ↑ Siegfried media release of June 27, 2016
- ↑ Siegfried media release of August 18, 2016
- ^ Press release Siegfried from October 4, 2016
- ^ Press release by Siegfried from October 27, 2016
- ↑ Siegfried media release of March 14, 2017
- ↑ Siegfried media release of March 21, 2017
- ↑ Siegfried media release of 23 August 2017
- ↑ Siegfried media release of October 28, 2017
- ↑ Press release Siegfried from March 14, 2018
- ↑ Siegfried media release of March 12, 2018